ECFSPR ENCOUNTER VARIABLES (vs 1.1)

Similar documents
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

UK Cystic Fibrosis Registry

Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses

Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Review)

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012

Cystic Fibrosis. History of Cystic Fibrosis. History of Cystic Fibrosis. Cystic Fibrosis. Salty Kiss

Palliative and Supportive Care in Cystic Fibrosis

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS

Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis

Antibiotic guideline in Adult Cystic Fibrosis

LRI Children s Hospital

Appendix D Clinical specialist statement template

UK Cystic Fibrosis Registry. Annual Data Report 2017

Bronchiectasis in Adults - Suspected

Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis

Supplementary Appendix

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

Cystic Fibrosis Registry of Ireland 2012 Annual Report

Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago

10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis

Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX

UK Cystic Fibrosis Registry

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD

Dutch Cystic Fibrosis Registy

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

Oral Cystic Fibrosis Modulators

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina

UK Cystic Fibrosis Registry Annual Data Report

Dose. Route. Units. Given. Dose. Route. Units. Given

A review of Cystic Fibrosis

Supplementary materials

Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)

"Management and Treatment of Patients with Cystic fibrosis (CF)

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)

CF: Information for Case Managers. Cindy Capen MSN, RN Pediatric Pulmonary Division University of Florida

NON-CF BRONCHIECTASIS IN ADULTS

Dr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher

CYSTIC FIBROSIS IN AUSTRALIA 2008

Dutch Cystic Fibrosis Registry

Online Supplement for:

Cystic fibrosis: From the gene to the disease

Management of bronchiectasis in adults

Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.

Fraser Health pandemic preparedness

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

2019 PHP PRIMARY CARE INCENTIVE

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

Eradication regimens for early or recurrent Pseudomonas aeruginosa infection

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017

Supplementary appendix

Navigating the Hills and Valleys of CF Lung Disease: Treating Disease

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Guideline for the Diagnosis and Management of COPD

Medical / Microbiology

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms

Children s Hospital, LHSC Cystic Fibrosis: Paediatric Clinic

Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7

Overview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist

Macrolide therapy in cystic fibrosis: new developments in clinical use

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Influenza-Associated Pediatric Deaths Case Report Form

At-A-Glance report 2014

At-A-Glance report 2013

The Alan Turing Institute. Mihaela van der Schaar Ahmed Alaa

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Admission of a Child/Young Person with Cystic Fibrosis Clinical Guideline V3.0 May 2018

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

Patient Name Date of Birth Age. Other phone ( ) . Other

TRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

BNF CHAPTER 3: RESPIRATORY

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE

FOR GENERAL PRACTITIONERS

UK Cystic Fibrosis Registry 2014 Annual Data Report

Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages)

BTS Guideline for non-cf Bronchiectasis

Chronic obstructive pulmonary disease

Background. Background. Background 3/14/2014. Conflict of Interest Statement:

WORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation

Non-cystic fibrosis bronchiectasis

Patient Registry. Annual Data Report

4.6 Small airways disease

Children s of Alabama. Birmingham, Alabama

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

Initiation Guide. Images not actual size.

UK Cystic Fibrosis Registry

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London

Inhaled Antibiotics in Non-CF. Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom

Antimicrobial Reference Laboratory

POLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.

Cystic Fibrosis. Presented by: Chris Belanger & Dylan Medd

Cystic Fibrosis Foundation Patient Registry 2013

Transcription:

European Cystic Fibrosis Society Patient Registry ECFSPR Encounter variables vs 1 ECFSPR ENCOUNTER VARIABLES (vs 1.1) Field Name Chapter title Sub chapter title Name Clinic (for visit) Date Coding Date of Encounter Date Calendar to select date: dd/mm/yyyy Doctor Date open field Weight (kg) Respir/Nutrit Numeric value in kg, to 1 decimal place (with point, not comma) Height (cm) Respir/Nutrit Numeric value in cm, without decimals Age as decimal (computed) Age in months (computed) automatic calculation automatic calculation Weight z-score Respir/Nutrit automatic calculation Weight age percentile Respir/Nutrit automatic calculation Height z-score Respir/Nutrit automatic calculation Height age percentile Respir/Nutrit automatic calculation BMI Respir/Nutrit automatic calculation BMI z-score Respir/Nutrit automatic calculation BMI percentile Respir/Nutrit automatic calculation FEV1 (litres) Respir/Nutrit record value in litres (two decimals, use '.' for decimals) of FEV1% predicted according to local reference values; (1) If unknown or not collected. FVC (litres) Respir/Nutrit record value in litres (two decimals, use '.' for decimals) of the FVC according to local reference values; (-1) Unkown Date of FEV1 measurement Respir/Nutrit dd/mm/yyyy FEF 25-75 (litres) Respir/Nutrit open field Value in L/sec (-1) Unkown FEV1% of predicted Respir/Nutrit automatic calculation FVC% of predicted Respir/Nutrit automatic calculation FEV1 / FVC Respir/Nutrit automatic calculation FEF 25-75% of predicted Respir/Nutrit automatic calculation 1

Result of LCI 2.5% Respir/Nutrit Value recorded at time of visit (-1) Unkown Month of LCI 2.5% measurement Respir/Nutrit mm Day of LCI 2.5% measurement Respir/Nutrit dd Device used for LCI measurement Respir/Nutrit t done (1) Ecomedics Exhalyzer D N2- Washout (2) Ecomedics Exhalyzer SF6 (Tracergas 4 %) (3) Innovision Innocor (4) NDD Easyone Pro Seen by Physiotherapist Respir/Nutrit Seen by Dietician Respir/Nutrit Seen by Psychotherapist Respir/Nutrit Maintenance Therapy Maintenance Nebulised Tobramycin Therapy Maintenance Nebulised Colomycin Therapy Maintenance Nebulised Aztreonam Therapy Maintenance Nebulised Levofloxacin (1) Continuously (2) Alternating monthly (1) Continuously (2) Alternating monthly (1) Continuously (2) Alternating monthly (1) Continuously (2) Alternating monthly

Tobramycin dry powder inhaler Therapy Maintenance Colomycin dry powder inhaler Therapy Maintenance (1) Continuously (2) Alternating monthly (1) Continuously (2) Alternating monthly Nebulised / dry powder antibiotics - Other Therapy Maintenance (1) Continuously (2) Alternating monthly Name of nebulised / dry powder antibiotics - Other Therapy Maintenance open field. Azithromycin / MacrolideMaintenance Therapy Therapy Maintenance (1) Azithromycine (2) Erythromycine (3) Clarithromycin] Chronic oral antibiotics Therapy Maintenance (1) Quinolone (Ciprofloxacin, Moxifloxacin, Levofloxacin, etc.) (2 Sulphonamide (trimethoprim/ sulfamethoxazole) (3) Cephalosporin (cephalexin, cefuroxime, cefaclor, etc.) (4) Penicillin (amoxicillin (including amoxicillin combination with clavulanic acid) (5) Flucloxacillin etc. (6) Tetracycline (doxycycline, minocycline etc) (7) Metronidazole (8) Clindamycin (9) Rifampicin (10) Sodium fusiadate (11) Chloramphenicol (12) Other + open field

Chronic antifungal therapy Therapy Maintenance (1) Itraconazole (2 Voriconazole (3) Posaconazole (4) Other + open field Use of rhdnase Therapy Respiratory Hypertonic saline Therapy Respiratory (1) 3% (2) 7% Use of Mannitol Therapy Respiratory Inhaled short acting bronchodilators Therapy Respiratory (1) Salbuterol (2) Terbutaline (3) Other Inhaled long acting bronchodilators Therapy Respiratory (1) Salbuterol (2) Other Inhaled steroid alone Therapy Respiratory (1) Fluticasone (2) Budesonide (3) Beclomethasone (4) Other Inhaled steroid with LABA Therapy Respiratory (1) Fluticasone - Salmeterol (2) Budesonide - Formoterol (3) Other Inhaled LAMA Therapy Respiratory (1) Tiotropium (2) Other

Inhaled nasal steroid Therapy Respiratory Oral steroid Therapy Respiratory High dose ibuprofen Therapy Respiratory Leukotrien receptor antagonist Therapy Respiratory Oxygen therapy Therapy Respiratory (1) During excercise (2) At night time (3) Continuous (4) Other Non-invasive positive pressure ventilation (NIPPV) Therapy Respiratory (1) CPAP (contin. positive airway pressure) (2) BPAP (bi-level positive airway pressure) Pancreatic enzyme replacement Therapy Nutrition / GI Ursodeoxycholic acid Therapy Nutrition / GI Proton pump inhibitors (PPI) Therapy Nutrition / GI H2 Blocker Therapy Nutrition / GI Appetite Stimulating Medication Therapy Nutrition / GI Enteral feeding Therapy Nutrition / GI (1) PEG (2) NG

Vitamin A supplements Therapy Nutrition / GI Vitamin D supplements Therapy Nutrition / GI Vitamin E supplements Therapy Nutrition / GI Vitamin K supplements Therapy Nutrition / GI Hormonal contraception Therapy Endocrine Calcium supplementation Therapy Endocrine Antidepressants Therapy Endocrine Bisphosphonate Therapy Endocrine Insulin Therapy Endocrine (1) Intermittant (2) Daily Oral Hypoglycemic Therapy Endocrine CFTR modifier therapy Therapy Other therapy (1) Ivacaftor (2) Orkambi (3) Symkevi (4) Other (specify) + text field If scrollbox Date of diagnosis of pulmonary exacerbation Stop date of pulmonary exacerbation Was patient treated with IV antibiotics for this Pulmonary Exacerbation? Exacerbation history Exacerbation history Exacerbation history Date field DD/MM/YYYY (calendar) Date field DD/MM/YYYY (calendar)

Was patient treated with Inhaled antibiotics for this Pulmonary Exacerbation? Exacerbation history Was patient hospitalized for this Pulmonary Exacerbation? Exacerbation history Oral antibiotic Exacerbation history Stop (selection of date) Continuing name (drop-down list) (1) Flucloxacillin (2) Other (please specify)] + open field Inhaled antibiotic Exacerbation history Start (selection of date) Stop (selection of date) Continuing name (drop-down list) (1) Amikacin (2) Aztreonam (3) Colistin (4) Flucloxacillin (5) Tobramycin (6) Gentamicin (7) Vancomycin (8) Other (please specify)] + open field Intravenous Exacerbation history Start (selection of date) Stop (selection of date) Continuing Drop-down list: (1) Amikacin (2) Aztreonam (3) Cefoxitin (4) Ceftazidime (5) Colistin (6) Flucloxacillin (7) Fosfamycin (8) Tobramycin (9) Gentamicin (10) Meropenem (11) Teicoplanin (12) Vancomycin (13) Cephradine; (14) Other (please specify) + open field Dropdownlist: Flucloxacillin Other (please specify)] + open field Unknown If YES drop-down list Drop-down list if YES

Hospitalisation Exacerbation history Admission (date) Discharge (date) Continuing Reason: (1) CF Pulmonary exacerbation (2) Other - CF related (3) Other-non CF related (4) CF related-hemoptysis (5) CF related-distal Intestinal Obstruction (6) Elective Surgery (7) CF related-pneumothorax (8) CF related-end Stage Lung Disease Hospitalisation planned Exacerbation history Hospitalisation admittance Exacerbation history (1 Clinic (2) Emergency Room If YES, dropdown list: Clinic Emergency Room Hospitalisation in ICU Exacerbation history Sample type Microbiology (1) OP swab (2) Spontaneous sputum (3) Bronchoscopy (4) Induced sputum (5) Pharyngeal aspiration (6) Other Start & End date If YES Drop down list: OP swab Spontaneous sputum Bronchoscopy Induced sputum Pharyngeal aspiration Other Sample date Microbiology Calendar to select date Has the subject tested positive for any of the following: Mucoid Pseudomonas aeruginosa Microbiology Non-mucoid Pseudomonas aeruginosa Microbiology

Staphylococcus aureus Microbiology MRSA Microbiology Burkholderia cepacia complex Microbiology Non-tuberculous mycobacteria Microbiology (1) MAC (2) Abscessus (3) Other Was Non-tuberculous mycobacteria cultured? Stenotrophomonas maltophilia Microbiology Achromobacter species xylosoxidans Microbiology Haemophilus influenzae (any species) Microbiology Other bacteria or fungus Microbiology (please specify) + open field ABPA Complications of CF (1) ABPA (2) ABPA requiring treatment If yes: dropdownlist: ABPA; ABPA requiring treatment Default: Unknown

Asthma Complications of CF DIOS Complications of CF (1) hospitalisation unknown (2) hospitalisation required (2) hospitalisation not required Glucose tolerance test done Complications of CF (1) Normal 2) Impaired glucose tolerance (3) Diabetic (4) Fasting hyperglycaemia (5) Yes, Other Pneumothorax requiring chest drain since last encounter Complications of CF Liver GI disease Complications of CF (1) Cirrhosis with portal hypertension 2) Cirrhosis without portal hypertension / hypersplenism (3) Cirrhosis portal hypertension unknown (4) Liver disease without cirrhosis (5) Variacel bleeding Hemoptysis more than 250ml since last encounter Complications of CF Pancreatitis Complications of CF Malignancy diagnosed since last encounter Complications of CF (99) Missing (1) Colorectal cancer (2) Small bowel cancer (3) Lymphoid leukemia (4) Testicular cancer (5) Breast cancer (6) Cancer of the Thyroid (7) Type unknown (8) Other (+ free text field ) If YES drop-down list:

Sinusitis Complications of CF Osteoporosis Complications of CF Osteopenia Complications of CF Gastroesophageal reflux Complications of CF Arthritis Complications of CF Anxiety Complications of CF Depression Complications of CF Salt loss syndrome Complications of CF

Comorbidities Complications of CF If YES drop-down list Date of lab sample: Liver Chemistries (LC) (1) Cardiac Arrhythmias (2 Cardiovascular Disease (including Heart failure) (3) Cholesterolemia (4) Chronic Pain (5) Constipation (6) Eye Disease (7) Cataract (8) Gall stone (9) Hearing Los (10) Hypertension with cholesterolemia (11) Hypertension without cholesterolemia (12) Pulmonary Arteria (13) Hypertension (14) Infertility (15) Micro gall bladder (16) Nasal polyp (17) Rectal prolapse (18) Renal disease (19) Nephrolithiasis (20) Renal disease Proteinuria (21) Renal disease Proteinuria requiring dialysis (22) Renal disease GFR <50% (23) Renal disease microalbuminuria dd/mm/yyyy ALT - Result: Liver Chemistries (LC) Unit: Liver Chemistries (LC) U/L; μmol/l AST Result: Liver Chemistries (LC) Unit: Liver Chemistries (LC) U/L; μmol/l GGT Result: Liver Chemistries (LC) Unit: Liver Chemistries (LC) U/L; μmol/l Alkaline Phosphatase Result: Liver Chemistries (LC) Unit: Liver Chemistries (LC) U/L; μmol/l BILIRUBIN Result: Liver Chemistries (LC) Unit: Liver Chemistries (LC) U/L; μmol/l Has the patient died since last encounter Vital status / Date of death Vital status / Vital Status (0) He/she died (1) He/she is alive Calendar to select date

Cause of death Vital status / (1) Respiratory (2) ation (3) Non-CF related (4) Liver GI (5) Trauma (6) Suicide (6) Non-CF related (7) Other (+ open text field) (cause of death not collected) Has the patient been assessed for, or had an active transplant since the last encounter Vital status / Reffered, awaiting assesment Vital status / Assessed, awaiting decision Vital status / Lung / Liver / Kidney / Other Lung / Liver / Kidney Decision made: unsuitable for listing Vital status / Lung / Liver / Kidney Decision made: on active list Vital status / ed Vital status / Lung / Liver / Kidney Lung / Liver / Kidney (date of transplant + tickbox Re-transplant not visible) (date of transplant + tickbox Retransplant not visible) (date of transplant + tickbox Re-transplant will become visible) Date of transplant Vital status / Lung / Liver / Kidney Calendar. Variable becomes visible when yes transplanted. Re-transplant Vital status / Lung / Liver / Kidney Tick box type Other transplant Drop down list Reffered, awaiting assesment Vital status / Other transplant Assessed, awaiting decision Vital status / Decision made: unsuitable for listing Vital status / Other transplant Other transplant

Decision made: on active list Vital status / ed Vital status / Other transplant Other transplant (date of transplant + tickbox Re-transplant not visible) (date of transplant + tickbox Retransplant not visible) (date of transplant + tickbox Re-transplant will become visible) Date of transplant Vital status / Re-transplant Vital status / Other transplant Other transplant Calendar Field becomes visible when yes transplanted. Did patient or caregiver reconsent/re-assent at any time? Re-consent / -Assent Date of written informed consent Re-consent / -Assent dd/mm/yyyy Informed CONSENT provided by: Re-consent / -Assent (0) Patient (1) Caregiver Did patient provide informed Assent? Re-consent / -Assent Date of informed Assent: Re-consent / -Assent dd/mm/yyyy Calendar Protocol version to which this consent/assent corresponds (please enter the version, e,g, 1.0, 2.0, etc.): Re-consent / -Assent text field